Updated:
Liaoning He Eye Hospital Group
Liaoning He Eye Hospital Group launched in 1995 in Shenyang, Liaoning, under the direction of Dr. He Wei, an ophthalmologist who later became a national...
Liaoning He Eye Hospital Group
Liaoning He Eye Hospital Group launched in 1995 in Shenyang, Liaoning, under the direction of Dr. He Wei, an ophthalmologist who later became a national political figure through membership on the Chinese People's Political Consultative Conference (CPPCC). The group's wealth is rooted in a growing network of specialty eye hospitals and clinics across China, supplemented by a full medical university campus — He University — that Dr. He established to train ophthalmic professionals and reinforce the group's talent pipeline. The group deploys capital across three integrated verticals: direct clinical operations, medical education infrastructure, and research. Its hospital network spans multiple Chinese provinces, including its base in Liaoning and an expansion into Guizhou through the Guizhou Health Industry Fund. The firm has pursued a niche strategy of blending Western ophthalmology with traditional Chinese medicine eye-care services, creating a differentiated clinical offering in the domestic market. A strategic partnership with Siasun Robot & Automation Co., Ltd., a Shenyang-based robotics firm in which Siasun holds a direct equity stake, signals an investment posture toward medical robotics for ophthalmic procedures. Dr. He Wei retains a 19.5% controlling stake, with family members Xiangdong He and Xingru He holding a combined interest above 11% and executive roles in the group, suggesting tight family governance. The share register also includes institutional co-investor SDIC Innovation Investment Management (6.6%) and business partner Lifang Fu (7.8%). The group operates from a headquarters in the Jiataihe International Building in central Shenyang, with additional real estate holdings in the city. Dr. He's board positions with the International Agency for the Prevention of Blindness (IAPB), the World Association of Eye Hospitals (WAEH), and the Ophthalmology Foundation connect the group to global ophthalmology policy and clinical exchange networks. What distinguishes Liaoning He Eye Hospital Group from a typical hospital chain is the tight integration of an operating company, an accredited medical university, and a platform for public-health philanthropy — all under a founder with a formal seat in China's top political advisory body. This structure makes the group simultaneously a healthcare provider, an educational institution, and a policy-shaping entity, a combination that is rare among private Chinese medical enterprises and shapes both its deal access and its regulatory posture.
General information
Firm type
Corporate Investor
Year founded
1995
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shenyang
Corporate office
Shenyang, Liaoning, China
Principals
He Wei
Chairman and CEO
Xiangdong He
Director
Xingru He
General Manager
Sector focus
Frequently asked questions
Who makes the key investment and strategic decisions at Liaoning He Eye Hospital Group?
Dr. He Wei, the founder, Chairman, and CEO, is the central decision-maker. He holds approximately 19.5% of the group and combines his clinical background with a political role as a member of the CPPCC National Committee. Major family shareholders Xiangdong He and Xingru He hold director and general manager roles respectively, indicating that investment and operating authority is concentrated within the founding family.
Does the group invest externally or only in its own operations?
The group's deployment is heavily weighted toward organic growth — opening new hospitals, funding He University, and supporting research. However, its participation in the Guizhou Health Industry Fund and its equity partnership with Siasun Robot & Automation demonstrate a willingness to deploy capital through external fund structures and strategic corporate investments when they align with healthcare technology goals.
How is the university related to the hospital business, and does it create a conflict of interest?
He University, which Dr. He founded, operates as a distinct entity but functions as an integrated talent and research pipeline for the hospital network. The university's campus is a separate real-estate asset in Shenyang's Hunnan District. This vertical integration provides a structural labor advantage in a market with scarce ophthalmic specialists, though allocators should note that the shared ownership and branding tie the university's reputation closely to the clinical network's performance.
What is the group's geographic footprint, and where is it expanding?
The hospital network is anchored in Liaoning province, with corporate offices in Shenyang's Huanggu and Yuhong districts. Expansion has reached Guizhou province through a dedicated health-industry investment fund. The group has not disclosed a target number of new hospitals, but its Guizhou activity indicates a southward expansion pattern from its northeast base.
What role does the CPPCC membership play in the group's operations?
Dr. He Wei's seat on the CPPCC National Committee gives the group's leadership direct access to China's political advisory processes on health policy. This is not a passive honorific: CPPCC members can influence regulatory frameworks and public-health spending priorities. For a private hospital chain, this connection can affect licensing speed, government procurement participation, and influence over public ophthalmology campaigns.
Does the group run a philanthropic program, and how is it separated from the for-profit operations?
The group operates He Eye Specialist Hospital Philanthropy Programs, which are distinct in mission from the core hospital business but linked by Dr. He's leadership and the clinical infrastructure. The philanthropy focuses on blindness prevention and community eye-care outreach, aligning with Dr. He's board role at the International Agency for the Prevention of Blindness. The degree of operational firewalling between the charity and the commercial hospitals is not publicly detailed.
Which sectors or investment types does the group explicitly avoid?
The group's investment activity has been almost entirely ophthalmology-centered healthcare services, education, and adjacent medical technology. There is no public record of the group making commitments to generalist venture capital, real estate development unrelated to its own operating needs, or non-healthcare private equity funds. Its narrow sector focus is a defining structural feature.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: